It can also be detected in patients with comorbid pathology.
Researchers obtained a small sample of skin from 74 patients who participated in the study. Photo: Shutterstock.
new one Research suggests that a skin test The minimally invasive approach can accurately diagnose Alzheimer’s disease with high sensitivity and specificity, even in the presence of concomitant conditions.
“The test, which measures factors related to synaptic connections in the brain, can be added to other tests to increase the certainty of making a diagnosis,” said Daniel Alcon, chief scientific advisor to SYN Associated PressS Dx, the company behind the test. Alzheimer’s disease. The findings were presented at the International Conference of the Association Alzheimer’s (AAIC) 2022.
According to the study, clinical trials testing potential AD treatments typically include: patients without a definite diagnosis Madness For EA, this is because diagnoses are often uncertain, especially during the first 4 to 5 years of illness.
Several tests have been developed to detect signs of AD, including magnetic resonance imaging and positron emission tomography tests for amyloid plaques, cerebrospinal fluid and plasma measurements of soluble amyloid.
While none of these tests have been widely validated in autopsies, the scientific advisor said, previous studies have shown that more than 50% patients Not only do they have AD, but they also have other pathologies, such as Parkinson’s disease, Madness frontal lobe or Madness Multiple myocardial infarction.
“It is not enough to discriminate for a test Alzheimer’s From a controlling person who is not crazy. It is valuable only if it can be distinguished from other types MadnessAlcon said.
He notes that beta-amyloid and tau are used as “pathological red flags” to identify Alzheimer’s disease. Alzheimer’s At autopsy, they are not excellent for definitive prognosis because they are not closely related to cognitive deficits. He added that there is an “absolute medical need” for a highly accurate and easily accessible AD biomarker.
One of the assays in trial is the morphometric imaging assay, which was previously shown to correlate closely with skin cell abnormalities. Madness and the presence of AD pathology in the brain patients with EA.
“The study deals with what’s going on in a patient’s mind,” Alcon said. “Have an estimate [que] There is a systemic manifestation of the disease; It affects not only the brain, but the entire system.”
In the current study, researchers obtained a small skin sample from 74 participants via a skin punch biopsy. 26 of these participants had AD, which was later confirmed after autopsy; was 21 Madness do not add (do not add); and 27 didn’t have Madness and served as a control group.
The researchers found that AD cell lines formed larger aggregates, whereas cell samples from the control or non-ADD group formed smaller and more numerous aggregates. The researchers then counted the number of aggregates and measured the average area of the aggregates.
This prompted them to separate patients From those without Eddie. The probability distribution of the morphometric imaging signals showed a clear separation for the measurements patients For individuals and group values with AD patients Add sin.
The researchers also used samples from patients Thief Madness Over 55 years of age and who had undergone blind autopsy. AD specificity was maintained even in cases with pathological comorbidities, including AD dementias such as Parkinson’s disease, Pick’s disease, and Alzheimer’s disease. Madness Of the frontal lobe.
“What’s new and unique is that we have shown that we can also measure eddy patients Those who have comorbidity, that is, patients who have these other dementias,” Alcon said.
Alcon pointed out that this type of Research It is time consuming and requires “resources, perseverance and determination”. An autopsy of death and confirmation may follow years later skin test and a clinical diagnosis.
“Clinicians should use all available measures in their arsenal that they can before diagnosing Alzheimer’s disease. Alzheimer’sAnd they need to be thorough and vigilant,” he said.
The company is currently seeking approval from skin test by the US Food and Drug Administration (FDA), and has received breakthrough status.
Testing can help rule out other causes Madness For which there are treatments, such as thyroid disorders, major depression and vitamin B12 deficiency, Alcon noted.
He acknowledged that if the test indicates AD, there are few effective treatments available. “In my opinion, none of the drugs currently available really treat the underlying disease,” he said.
Source consulted here.